A Pilot Study of Acalabrutinib With Bendamustine/Rituximab Followed by Cytarabine/Rituximab for Untreated Mantle Cell Lymphoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 04期
关键词：
TRIAL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [21] Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab
    Ramsower, Colleen A.
    Rosenthal, Allison
    Robetorye, Ryan S.
    Mwangi, Raphael
    Maurer, Matthew
    Villa, Diego
    McDonnell, Tim
    Feldman, Andrew
    Cohen, Jonathon B.
    Habermann, Thomas
    Campo, Elias
    Clot, Guillem
    Buhler, Marco M.
    Kulis, Marta
    Martin-Subero, Jose Ignacio
    Gine, Eva
    Cook, James R.
    Hill, Brian
    Raess, Philipp W.
    Beiske, Klaus H.
    Reichart, Alexander
    Hartmann, Sylvia
    Holte, Harald
    Scott, David
    Rimsza, Lisa
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (01) : 160 - 170
  • [22] RITUXIMAB AND HIGH DOSE CYTARABINE WITH AUTOLOGOUS TRANSPLANTATION FOR MANTLE CELL LYMPHOMA
    Burrows, S.
    Tucker, D.
    Naylor, G.
    Wardrope, K.
    Bolam, S.
    McKay, P.
    Forbes, A.
    Rule, S.
    HAEMATOLOGICA, 2016, 101 : 398 - 399
  • [23] Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma
    Romaguera, Jorge
    Fayad, Luis
    McLaughlin, Peter
    Pro, Barbara
    Rodriguez, Maria Alma
    Wang, Michael
    Weaver, Pamela
    Hartig, Kimberly
    Kwak, Larry
    Feldman, Tatyana
    Smith, Judy
    Ford, Peggy
    Goldberg, Stuart
    Pecora, Andrew
    Goy, Andre
    BLOOD, 2008, 112 (11) : 1049 - 1049
  • [24] RITUXIMAB, BENDAMUSTINE AND CYTARABINE AS INDUCTION THERAPY IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA: A PHASE 2 STUDY FROM THE FONDAZIONE ITALIANA LINFOMI
    Visco, C.
    Chiappella, A.
    Franceschetti, S.
    Patti, C.
    Ferrero, S.
    Barbero, D.
    Evangelista, A.
    Spina, M.
    Molinari, A.
    Rigacci, L.
    Tani, M.
    Di Rocco, A.
    Pinotti, G.
    Fabbri, A.
    Zambello, R.
    Finotto, S.
    Gotti, M.
    Carella, A. M.
    Salvi, F.
    Pileri, S. A.
    Ladetto, M.
    Zaja, F.
    Gaidano, G.
    Vitolo, U.
    Rodeghiero, F.
    HAEMATOLOGICA, 2015, 100 : 4 - 4
  • [25] Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
    Villa, Diego
    Hoster, Eva
    Hermine, Olivier
    Klapper, Wolfram
    Szymczyk, Michal
    Bosly, Andre
    Unterhalt, Michael
    Rimsza, Lisa M.
    Ramsower, Colleen A.
    Freeman, Ciara L.
    Scott, David W.
    Gerrie, Alina S.
    Savage, Kerry J.
    Sehn, Laurie H.
    Dreyling, Martin
    BLOOD ADVANCES, 2022, 6 (18) : 5285 - 5294
  • [26] Phase I trial of bortezomib in combination with rituximab-HyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma
    Romaguera, J. E.
    Pro, B.
    Fayad, L.
    McLaughlin, P.
    Wang, M.
    Weaver, P.
    Hartig, K.
    Hagemeister, F.
    Rodriguez, M. A.
    Younes, A.
    Samaniego, F.
    Fanale, M.
    Kwak, L.
    Feldman, T.
    Goy, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 214 - 214
  • [27] Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis
    Yi, Jun Ho
    Kim, Seok Jin
    Lee, Jeong-ok
    Lee, Gyeong-won
    Kwak, Jae-yong
    Eom, Hyeon-seok
    Jo, Jae-cheol
    Choi, Yoon Seok
    Oh, Sung Yong
    Kim, Won Seog
    ANTICANCER RESEARCH, 2022, 42 (12) : 6083 - 6089
  • [28] Effects of Rituximab, Bortezomib, and Bendamustine on the Survival in Medicare Beneficiaries with Mantle Cell Lymphoma
    Fu, Shuangshuang
    Wang, Michael
    Zhao, Hui
    Li, Ruosha
    Lairson, David
    Giordano, Sharon
    Zhao, Bo
    Du, Xianglin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S273 - S274
  • [29] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [30] Bendamustine and rituximab for the treatment of relapsed indolent and mantle cell lymphoma: when timing of a study matters
    Falchi, Lorenzo
    Morales, Rita
    Ruella, Marco
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S590 - S594
12345